



## Sanofi Pasteur to Provide 1.7 Billion Doses of Oral Polio Vaccine from 2013 to 2017 for Polio Eradication

*- Company also expands injectable polio vaccine production capacity to respond to the World Health Organization's endgame strategy -*

**Lyon, France – April 24, 2013** – Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced today its commitment to provide 1.7 billion doses of oral polio vaccine (OPV) to support the Global Polio eradication Initiative's (GPEI) strategy to eradicate polio this decade. The doses of OPV will be delivered through 2017 for GPEI polio vaccination program.

In addition to OPV campaigns, the World Health Organization's (WHO) expert group on immunization (SAGE) recommends that all countries introduce at least one dose of injectable inactivated polio vaccine (IPV) in routine polio immunization programs. Sanofi Pasteur is responding to this strategy with the expansion of production capacities of IPV.

*"Wiping out polio for good is in sight and Sanofi Pasteur intends to remain an active contributor to achieve zero polio,"* said Olivier Charmeil, President and CEO of Sanofi Pasteur. *"We believe that the introduction of IPV in routine polio immunization will consolidate the tremendous progress achieved over the last decades and ensure a polio-free world for the future. Sanofi Pasteur has been a leading provider of polio vaccines and a supporter of the Global Polio Eradication Initiative for over 20 years. We intend to continue to be a major supporter of WHO and its partners to finish the job."*

As a result of vaccination, polio cases have been reduced by 99% over 20 years, saving millions of children from paralysis. The GPEI has set the goal of eradicating the disease completely. Today only a few countries are still affected by polio.

*"A strong and steady supply of polio vaccines will ensure that every child is fully protected against polio,"* said John Hewko, General Secretary of the humanitarian service organization Rotary International, a spearheading partner in the polio eradication initiative. *"Sanofi Pasteur's commitment of 1.7 billion vaccine doses comes at a crucial moment as we make the final push needed to end polio once and for all. On behalf of Rotary's 1.2 million members worldwide, I commend and thank Sanofi Pasteur for its steadfast support."*

Polio vaccination protects against disease from all three types of polio virus. SAGE now recommends that all countries introduce at least one dose of IPV in routine polio immunization programs to mitigate the risk of circulating vaccine-derived poliovirus (cVDPV). The introduction of IPV will pave the way for the cessation of oral poliovirus vaccine type 2 (OPV2) since wild poliovirus type 2 has already been eliminated. It is hoped that, with this new vaccination schedule, wild poliovirus types 1 and 3 will also be eradicated within the next few years.



### **About the Global Polio Eradication Initiative**

Since 1988, the Global Polio Eradication Initiative, spearheaded by WHO, Rotary International, the US Centers for Disease Control and Prevention (CDC) and UNICEF -- with additional support from the Bill & Melinda Gates Foundation -- has achieved a 99% reduction of the number of polio cases worldwide. Polio is caused by three strains of poliovirus, types 1, 2 and 3. Wild poliovirus type 2 has already been eliminated, and it is hoped that poliovirus type 1 and 3 will be eradicated within a few years, definitively wiping polio from the surface of the earth.

### **Sanofi Pasteur in the fight against polio**

Sanofi Pasteur has been supporting the Global Polio Eradication Initiative since its launch in 1988. Over the past decades, Sanofi Pasteur has supplied more than 5 billion doses of OPV to UNICEF.

In response to an outbreak in Egypt and a request from WHO, the company developed the first monovalent oral polio vaccine, which helped in declaring Egypt polio free in 2006. Between 1997 and 2005, Sanofi Pasteur donated over 120 million doses of OPV to respond to emergency situations in African countries affected by conflicts.

Sanofi Pasteur is a leading supplier of IPV, available as a stand-alone poliovirus vaccine as well as a component of combination pediatric vaccines to immunize against many diseases in a single shot.

### **Rotary and polio eradication**

Rotary is a global humanitarian service organization with more than 1.2 million members in 200 countries and geographical areas. Rotary members are men and women who are leaders in their businesses, professions, and communities, united by their commitment to improve the world through volunteer service. Rotary's top priority is the global eradication of polio. To date Rotary club members have contributed more than \$1.2 billion and countless volunteer hours to immunize the world's children against polio.

### **About Sanofi**

Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Sanofi Pasteur, the vaccines division of Sanofi, provides more than 1 billion doses of vaccine each year, making it possible to immunize more than 500 million people across the globe. A world leader in the vaccine industry, Sanofi Pasteur offers the broadest range of vaccines protecting against 20 infectious diseases. The company's heritage, to create vaccines that protect life, dates back more than a century. Sanofi Pasteur is the largest company entirely dedicated to vaccines. Every day, the company invests more than EUR 1 million in research and development. For more information, please visit: [www.sanofipasteur.com](http://www.sanofipasteur.com) or [www.sanofipasteur.us](http://www.sanofipasteur.us)

### **Forward Looking Statements**

*This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally*



beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2012. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

---

## Contacts:

### Global Media Relations

Pascal Barollier

T. +33-(0)4-37-37-50-38

[pascal.barollier@sanofipasteur.com](mailto:pascal.barollier@sanofipasteur.com)

[www.sanofipasteur.com](http://www.sanofipasteur.com)

### U.S. Media Relations

Len Lavenda

T. +1-570-957-0717

[len.lavenda@sanofipasteur.com](mailto:len.lavenda@sanofipasteur.com)

[www.sanofipasteur.us](http://www.sanofipasteur.us)